0001062993-24-006058.txt : 20240308 0001062993-24-006058.hdr.sgml : 20240308 20240308182955 ACCESSION NUMBER: 0001062993-24-006058 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240306 FILED AS OF DATE: 20240308 DATE AS OF CHANGE: 20240308 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farid Adrienne CENTRAL INDEX KEY: 0001867310 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40498 FILM NUMBER: 24736063 MAIL ADDRESS: STREET 1: C/O CENTURY THERAPEUTICS, INC. STREET 2: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Century Therapeutics, Inc. CENTRAL INDEX KEY: 0001850119 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 842040295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 25 N 38TH STREET, 11TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-981-4000 MAIL ADDRESS: STREET 1: 25 N 38TH STREET, 11TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-03-06 0001850119 Century Therapeutics, Inc. IPSC 0001867310 Farid Adrienne C/O CENTURY THERAPEUTICS, INC. 25 N 38TH STREET, 11TH FLOOR PHILADELPHIA PA 19104 0 1 0 0 Chief Operations Officer 0 Common Stock 2024-03-06 4 M 0 30684 1.03 A 144833 D Common Stock 2024-03-06 4 S 0 30684 4.9648 D 114149 D Common Stock 2024-03-07 4 M 0 22831 1.03 A 136980 D Common Stock 2024-03-07 4 S 0 22831 5.1396 D 114149 D Stock Option (right to buy) 1.03 2024-03-06 4 M 0 30684 0 D 2029-07-17 Common Stock 30684 191486 D Stock Option (right to buy) 1.03 2024-03-07 4 M 0 22831 0 D 2029-07-17 Common Stock 22831 168655 D The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 17, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.85 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.87 to $5.48, inclusive. The option is fully vested and exercisable. /s/ Adrienne Farid 2024-03-08